Provided by Tiger Fintech (Singapore) Pte. Ltd.

Galmed Pharmaceuticals

1.30
-0.0700-5.11%
Pre-market: 1.330.0200+1.53%09:15 EDT
Volume:641.59K
Turnover:882.43K
Market Cap:2.94M
PE:-0.16
High:1.42
Open:1.36
Low:1.30
Close:1.37
Loading ...

Analysts Conflicted on These Healthcare Names: Galmed Pharmaceuticals (GLMD) and Regeneron (REGN)

TIPRANKS
·
29 Apr

BUZZ-U.S. STOCKS ON THE MOVE-Marriott, Wells Fargo, Insulet

Reuters
·
28 Apr

Dow Jumps Over 150 Points; Domino's Pizza Posts Upbeat Earnings

Benzinga
·
28 Apr

BRIEF-Galmed Signed Term Sheet For The Development Of Novel Semaglutide Sublingual Formulation

Reuters
·
28 Apr

Galmed Pharmaceuticals Ltd - New Formulation Offers Non-Invasive Alternative to Injectable Semaglutide

THOMSON REUTERS
·
28 Apr

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

PR Newswire
·
28 Apr

BRIEF-Galmed Pharmaceuticals Launches VCU Collaboration To Tackle Drug Resistance In Gi Cancers

Reuters
·
17 Apr

Galmed Pharmaceuticals Launches Vcu Collaboration to Tackle Drug Resistance in Gi Cancers

THOMSON REUTERS
·
17 Apr

Galmed Pharmaceuticals Unveils New Blood Markers for Aramchol

TIPRANKS
·
15 Apr

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

PR Newswire
·
15 Apr

Galmed Pharmaceuticals Ltd: Aramchol Meglumine Received Nce Patent Protection Extending Until 2035

THOMSON REUTERS
·
10 Apr

Galmed Announces Positive Part 1 Results From the Am-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced Scd1 Inhibitor

THOMSON REUTERS
·
10 Apr

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor

PR Newswire
·
10 Apr

BUZZ-Galmed Pharmaceuticals falls after Maxim downgrade

Reuters
·
05 Apr

Galmed Pharmaceuticals Cut to Hold From Buy by Maxim Group

Dow Jones
·
04 Apr

Galmed downgraded to Hold from Buy at Maxim

TIPRANKS
·
04 Apr

Galmed Pharmaceuticals Ltd : Maxim Group Cuts to Hold From Buy

THOMSON REUTERS
·
04 Apr

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

PR Newswire
·
03 Apr

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in Nash/Mash Combination Therapy

THOMSON REUTERS
·
20 Mar

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy

PR Newswire
·
20 Mar